Supports

Ocrelizumab Overview

Introduction of Ocrelizumab

Ocrelizumab is a novel humanized antibody targeting the B lymphocytes that express the CD20 antigen. It is designed through recombinant DNA technology and has shown promising results in the treatment of relapsing (RMS) or primary progressive (PPMS) forms of multiple sclerosis, rheumatoid arthritis, lupus erythematosus and hematological cancer. Due to its mostly human origin, ocrelizumab is expected to induce less immunogenicity and theoretically is expected to cause fewer anti-drug antibodies to be formed, as well as milder infusion reactions. OCREVUS™, the first ocrelizumab drug developed by Genentech/Roche for intravenous injection has been successively approved by Food and Drug Administration (in March 2017), Health Canada (in August 2017), and European Medicines Agency (in January 2018) for the treatment of multiple sclerosis.

Mechanism of Action of Ocrelizumab

The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-, naïve, mature, and memory B cells, which are known to contribute to the pathogenesis of multiple sclerosis through activation of pro-inflammatory T cells and secretion of proinflammatory cytokines. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis involving macrophages, natural killer cells, and cytotoxic T cells that act together to cause cell death. Another mechanism is apoptosis, which may result from cross-linking membrane CD20 on the target cell surface.

Fig. 1 Mechanism of Action of Ocrelizumab
The image shows the various mechanism in the pathogenesis of multiple sclerosis and the various drugs that are being developed as potential therapies for multiple sclerosis.

Clinical Projects of Ocrelizumab*

NCT ID	Status	Conditions	Lead Sponsor	Update Time
NCT03085810	Recruiting	Multiple Sclerosis, Relapsing-Remitting	Hoffmann-La Roche	March 21, 2017
NCT02637856	Recruiting	Multiple Sclerosis, Relapsing-Remitting	Genentech, Inc.	December 22, 2015
NCT03025269	Enrolling by invitation	Multiple Sclerosis	University at Buffalo	January 19, 2017
NCT02688985	Recruiting	Relapsing Multiple Sclerosis	Genentech, Inc.	February 23, 2016
NCT03344094	Recruiting	Multiple Sclerosis	University of Chicago	November 17, 2017
NCT02980042	Recruiting	Multiple Sclerosis	University of Colorado, Denver	December 2, 2016
NCT01194570	Active, not recruiting	Multiple Sclerosis, Primary Progressive	Hoffmann-La Roche	September 3, 2010
NCT03157830	Recruiting	Relapsing Remitting Multiple Sclerosis	Providence Health & Services	May 17, 2017
NCT01412333	Active, not recruiting	Relapsing Multiple Sclerosis	Hoffmann-La Roche	August 9, 2011
NCT03396822	Not yet recruiting	Multiple Sclerosis	University of Maryland	January 11, 2018
NCT00676715	Active, not recruiting	Multiple Sclerosis, Relapsing-Remitting	Genentech, Inc.	May 13, 2008
NCT03138525	Recruiting	Multiple Sclerosis	Brigham and Women's Hospital	May 3, 2017
NCT02545868	Active, not recruiting	Multiple Sclerosis, Relapsing-Remitting	Hoffmann-La Roche	September 10, 2015
NCT00476996	Active, not recruiting	Rheumatoid Arthritis	Genentech, Inc.	May 22, 2007

Approved Drugs of Ocrelizumab**

INN (trade name)	Therapeutic area	Dosage	Strength	Route	Company	Marketing start	Market
Ocrevus	Multiple Sclerosis	Injection	300 mg/10mL	Intravenous	Genentech, Inc.	March 28, 2017
Ocrevus	Multiple Sclerosis	Solution	30 mg	Intravenous	Hoffmann La Roche	September 21, 2017
Ocrevus	Multiple Sclerosis	Injection	300 mg/10mL	Intravenous	Roche Registration Limited	January 8, 2018

INN, International nonproprietary name.

What We Provide

Therapeutic Antibody

Ocrelizumab

We provide high-quality ocrelizumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Ocrelizumab

** Information presented in the table was collected from the following websites:
https://www.drugbank.ca/drugs/DB11988
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004043/human_med_002187.jsp

For research use only. Not intended for any clinical use.